Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02737826 · ClinicalTrials.gov registry record · NA
Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper
A NA study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT02737826: Completed NA study, sponsored by Medical University of South Carolina.
NCT02737826 is a NA study that has completed, run by Medical University of South Carolina. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02737826, a NA study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Chronic opioid therapy for pain can be associated with significant risks, and a significant number of patients maintained on chronic opioids have continued pain and/or poor functioning. When patients need to or want to come off their opioid pain medications, there is little to guide physicians as to how to best help them do so, and it is not known how patients do after coming off opioid medications. The goals of this study are (1) to evaluate two medications in assisting patients in coming off their opioid pain medications and (2) determining outcomes after discontinuing opioids.
Primary Outcome
For Phase I, the primary outcome measure is the percentage of patients who tolerate buprenorphine initiation within an 8-hour initiation period, as evidenced by a total score of 3 points when summing the following measures (1) moderate-good level of pain control (same or improved rating on a 0-10 visual analogue scale for pain) = 1 point, (2) mild to no withdrawal symptoms (≤10 on the Subjective Opioid Withdrawal Scale) = 1 point, and (3) willingness to continue to the stabilization and tapering
Interventions
- DRUG Buprenorphine Initiation - Phase I
- DRUG Gabapentin + Buprenorphine - Phase II
- DRUG Placebo + Buprenorphine - Phase II
- DRUG Buprenorphine taper - Phase II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-01-13 |
| Phase | NA |
What the finished NCT02737826 record still lists
NCT02737826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Buprenorphine Initiation - Phase I is the first listed.
NCT02737826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02737826 about?
NCT02737826 is a clinical study titled "Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper". Chronic opioid therapy for pain can be associated with significant risks, and a significant number of patients maintained on chronic opioids have continued pain and/or poor functioning. When patients need to or want to come off their opioid pain medications, there is little to guide physicians as to...
What is the current status of trial NCT02737826?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2016-05. Estimated completion is 2021-01-13.
What interventions are being tested in trial NCT02737826?
The interventions under investigation include: Buprenorphine Initiation - Phase I (DRUG), Gabapentin + Buprenorphine - Phase II (DRUG), Placebo + Buprenorphine - Phase II (DRUG), Buprenorphine taper - Phase II (DRUG).
Who is sponsoring clinical trial NCT02737826?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02737826's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia